Exclusive Summary

• Rare mechanism perfectly aligned with obesity pain points: UB666 is a monoclonal antibody modulating the negative regulators of skeletal muscle growth. It zeroes in on sarcopenic obesity, completely offsetting the severe muscle-wasting flaw of current GLP-1 weight-loss blockbusters.
• Innovative PK extension design: Engineered with a pH-dependent antigen-binding profile, the antibody drops its target in the acidic environment (pH 5.8) of lysosomes and recycles back into circulation, substantially extending its in vivo half-life.
• Distinct specificity translating to high safety profiling: It exerts exceptionally low binding potency toward latent GDF11 and mature GDF11/GDF8 forms, which drastically averts off-target toxicities typically associated with systemic growth factor inhibitions.
• Competing strongly with global benchmarks for immense commercial potential: Currently at the Preclinical Candidate (PCC) stage, its in vitro cross-species high affinities match those of prestigious tier-1 competitors (e.g., SRK-015, GYM329). It represents a pristine licensing opportunity for top MNCs building muscle-preserving combo therapies.

Asset Materials

Contact Us for Full Materials